Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Minerva Cardiol Angiol ; 2022 Jun 29.
Article in English | MEDLINE | ID: covidwho-1912554

ABSTRACT

SARS-CoV-2 mainly affects the respiratory system, from mild upper respiratory symptoms in acute respiratory distress syndrome. However, a significant amount of evidence has demonstrated that Coronavirus disease 2019 affects the cardiovascular system in many ways and has manifestations ranging from asymptomatic increases in cardiac biomarkers for cardiovascular and cardiac collapse arrest. The primary diagnostic method of COVID-19 is reverse transcription polymerase chain reaction of the nucleic acid of SARS-CoV-2 in nasopharyngeal swabs. There is growing evidence regarding the 2019 coronavirus disease imaging results on chest x-rays and computed tomography but the accessibility to standard diagnostic methods may be limited during the pandemic. Consequently, the significance and potential of bedside diagnostic modalities increases, including pulmonary and cardiac ultrasound, that are cost-effective, widely available, and provide information that can influence management. This review summarizes wide pattern of cardiac and pulmonary anomalies diagnosed by ultrasound, comparing them with other imaging methods such as magnetic resonance and computed tomography, discusses the possible mechanisms involved and the prognostic role.

2.
Eur Heart J Case Rep ; 5(2): ytaa518, 2021 Feb.
Article in English | MEDLINE | ID: covidwho-1010349

ABSTRACT

BACKGROUND: COVID-19 may induce a coagulation dysregulation resulting in a prothrombotic state with a higher risk of arterial and venous thrombosis. This abnormal thrombotic diathesis can lead to pulmonary embolism, stroke, and intracardiac thrombosis. CASE SUMMARY: We present two cases of unusual intracardiac thrombosis in patients hospitalized for COVID-19. In both cases, imaging tests (such as transthoracic echocardiography (TTE), computed tomography scan of the chest, and cardiac magnetic resonance imaging) showed evidence of unusual intracardiac thrombosis with thrombi adherent to regularly contracting walls. DISCUSSION: This evidence confirms that COVID-19 induces a hypercoagulable state which can result in intracardiac thrombosis. Therefore, TTE is indicated in all COVID-19 patients for early diagnosis, and prompt anticoagulant therapy is to be considered as a thromboprophylaxis strategy.

3.
G Ital Cardiol (Rome) ; 21(8): 565-569, 2020 Aug.
Article in Italian | MEDLINE | ID: covidwho-680055

ABSTRACT

In Italy, the epidemic explosion stage of COVID-19 seems to have been overcome; however, the virus has not been eradicated and the re-emergence of some outbreaks of infection substantiates the danger that the disease may persist. It is therefore necessary to keep the level of surveillance high, to maintain social distancing measures and to act in the control of disease risk factors of a serious or complicated course. Among the risk factors of severe COVID-19 in addition to age, male gender, hypertension and cardiovascular diseases, a major role seems to be played by other cardiovascular risk factors conditioned by an unhealthy lifestyle such as obesity, metabolic syndrome, diabetes and smoking. The new phase requires the maintenance of measures that avoid crowding and close interpersonal contact especially during exercise, in addition to controlled access to hospitals. This will require the reorganization of the traditional methods of cardiovascular prevention and rehabilitation activities, such as gyms and collective educational sessions, and the dilution of outpatient checks. The risk that this scenario may worsen the already suboptimal control of cardiovascular risk factors is therefore real. We do not currently know how long this new phase will last, therefore it is necessary to give impetus to new tele-health initiatives to stimulate the adoption of a healthy lifestyle in primary prevention and tele-monitoring and tele-rehabilitation programs in secondary prevention.


Subject(s)
Cardiovascular Diseases/epidemiology , Communicable Disease Control/organization & administration , Coronavirus Infections/epidemiology , Pandemics/statistics & numerical data , Pneumonia, Viral/epidemiology , Telemedicine/organization & administration , COVID-19 , Cardiologists , Cardiovascular Diseases/diagnosis , Coronavirus Infections/prevention & control , Female , Follow-Up Studies , Hospitals, University , Humans , Italy/epidemiology , Male , Pandemics/prevention & control , Physician's Role , Pneumonia, Viral/prevention & control , Risk Assessment , Time Factors
4.
Eur Heart J ; 41(19): 1821-1829, 2020 05 14.
Article in English | MEDLINE | ID: covidwho-615402

ABSTRACT

AIMS: To compare demographic characteristics, clinical presentation, and outcomes of patients with and without concomitant cardiac disease, hospitalized for COVID-19 in Brescia, Lombardy, Italy. METHODS AND RESULTS: The study population includes 99 consecutive patients with COVID-19 pneumonia admitted to our hospital between 4 March and 25 March 2020. Fifty-three patients with a history of cardiac disease were compared with 46 without cardiac disease. Among cardiac patients, 40% had a history of heart failure, 36% had atrial fibrillation, and 30% had coronary artery disease. Mean age was 67 ± 12 years, and 80 (81%) patients were males. No differences were found between cardiac and non-cardiac patients except for higher values of serum creatinine, N-terminal probrain natriuretic peptide, and high sensitivity troponin T in cardiac patients. During hospitalization, 26% patients died, 15% developed thrombo-embolic events, 19% had acute respiratory distress syndrome, and 6% had septic shock. Mortality was higher in patients with cardiac disease compared with the others (36% vs. 15%, log-rank P = 0.019; relative risk 2.35; 95% confidence interval 1.08-5.09). The rate of thrombo-embolic events and septic shock during the hospitalization was also higher in cardiac patients (23% vs. 6% and 11% vs. 0%, respectively). CONCLUSIONS: Hospitalized patients with concomitant cardiac disease and COVID-19 have an extremely poor prognosis compared with subjects without a history of cardiac disease, with higher mortality, thrombo-embolic events, and septic shock rates.


Subject(s)
Coronavirus Infections/mortality , Heart Diseases/mortality , Hospitalization , Pneumonia, Viral/mortality , Aged , Aged, 80 and over , Atrial Fibrillation , Betacoronavirus , COVID-19 , Coronavirus Infections/complications , Creatinine/blood , Female , Heart Diseases/complications , Heart Failure , Humans , Italy/epidemiology , Male , Middle Aged , Natriuretic Peptide, Brain/blood , Pandemics , Peptide Fragments/blood , Pneumonia, Viral/complications , Prognosis , Respiratory Distress Syndrome , Risk Factors , SARS-CoV-2 , Shock, Septic , Thromboembolism , Troponin T/blood
5.
Monaldi Arch Chest Dis ; 90(2)2020 Jun 15.
Article in English | MEDLINE | ID: covidwho-603594

ABSTRACT

The COVID-19 outbreak is having a significant impact on both cardiac rehabilitation (CR) inpatient and outpatient healthcare organization. The variety of clinical and care scenarios we are observing in Italy depends on the region, the organization of local services and the hospital involved. Some hospital wards have been closed to make room to dedicated beds or to quarantine the exposed health personnel. In other cases, CR units have been converted or transformed into COVID-19 units.  The present document aims at defining the state of the art of CR during COVID-19 pandemic, through the description of the clinical and management scenarios frequently observed during this period and the exploration of the future frontiers in the management of cardiac rehabilitation programs after the COVID-19 outbreak.


Subject(s)
Cardiac Rehabilitation/standards , Coronavirus Infections/epidemiology , Pneumonia, Viral/epidemiology , Acute Coronary Syndrome/rehabilitation , COVID-19 , Cardiac Rehabilitation/psychology , Cardiotonic Agents/adverse effects , Cardiotonic Agents/therapeutic use , Exercise , Female , Heart Failure/rehabilitation , Humans , Italy/epidemiology , Male , Nutrition Therapy , Pandemics , Thromboembolism/rehabilitation
6.
JACC Case Rep ; 2(9): 1359-1364, 2020 Jul 15.
Article in English | MEDLINE | ID: covidwho-597754

ABSTRACT

Left ventricle thrombus is considered a rare complication of Takotsubo syndrome. However, both a stress condition predisposing to Takotsubo syndrome and coagulation abnormalities coexist in COVID-19. We describe a case of a patient with COVID-19 with Takotsubo syndrome. (Level of Difficulty: Intermediate.).

7.
Int J Cardiol ; 313: 129-131, 2020 08 15.
Article in English | MEDLINE | ID: covidwho-259358

ABSTRACT

There is some evidence that Covid 19 pneumonia is associated with prothrombotic status and increased risk of venous thromboembolic events (deep venous thrombosis and pulmonary embolism). Over a two-week period we admitted in our Unit 25 patients with Covid-19 pneumonia, of these pulmonary embolism was diagnosed using computed tomography angiography in 7. We report on clinical and biochemical features of these patients. They were all males, with a mean age of 70.3 years (range 58-84); traditional risk factors for venous thromboembolism were identified in the majority of patients with pulmonary embolism, however not differently from those without pulmonary embolism. Clinical presentation of pulmonary embolism patients was usually characterized by persistence or worsening of respiratory symptoms, with increasing oxygen requirement. D-dimer levels were several fold higher than the upper threshold of normal; in patients in whom PE was recognized during hospital stay, a rapid and relevant increase of D-dimer levels was observed. Computed tomographic findings ranged from massive acute pulmonary embolism to a segmental or sub-segmental pattern; furthermore, thrombosis of sub-segmental pulmonary arteries within lung infiltrates were occasionally seen, suggesting local mechanisms. Six out of 7 patients were treated with unfractionated or low molecular weight heparin with clinical benefit within few days; one patient needed systemic thrombolysis (death from hemorrhagic complication).


Subject(s)
Coronavirus Infections , Fibrin Fibrinogen Degradation Products/analysis , Heparin/administration & dosage , Pandemics , Pneumonia, Viral , Pulmonary Embolism , Venous Thromboembolism , Aged , Anticoagulants/administration & dosage , Betacoronavirus/isolation & purification , COVID-19 , Comorbidity , Computed Tomography Angiography/methods , Coronavirus Infections/blood , Coronavirus Infections/epidemiology , Coronavirus Infections/physiopathology , Coronavirus Infections/therapy , Female , Humans , Incidence , Italy/epidemiology , Male , Outcome and Process Assessment, Health Care , Oxygen/blood , Pneumonia, Viral/blood , Pneumonia, Viral/diagnosis , Pneumonia, Viral/epidemiology , Pneumonia, Viral/etiology , Pneumonia, Viral/physiopathology , Pneumonia, Viral/therapy , Pulmonary Embolism/epidemiology , Pulmonary Embolism/etiology , Pulmonary Embolism/physiopathology , Pulmonary Embolism/therapy , SARS-CoV-2 , Sex Factors , Venous Thromboembolism/complications , Venous Thromboembolism/diagnosis , Venous Thromboembolism/epidemiology , Venous Thromboembolism/therapy
8.
Monaldi Arch Chest Dis ; 90(1)2020 Apr 16.
Article in English | MEDLINE | ID: covidwho-66257

ABSTRACT

The ongoing COVID-19 pandemic spreading all around the world has stressed over its capabilities and determined profound changes in the health systems in all countries and has caused hundreds of thousand deaths. Health professionals have been called to a tremendous effort to deal with this emergency, often contaminating or succumbing themselves to the disease.


Subject(s)
Cardiac Rehabilitation , Coronavirus Infections/epidemiology , Pneumonia, Viral/epidemiology , Betacoronavirus , COVID-19 , Humans , Pandemics , Public Health , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL